The Drug Enforcement Administration has recommended reclassifying botanical cannabis from Schedule I to Schedule III under federal law, citing its safe and effective therapeutic benefits. This decision follows the US Department of Health and Human Services advocating for the change, marking the first time a President has requested such a review. NORML Deputy Director Paul Armentano emphasized the need for federal policy reform to align with state laws regulating cannabis. However, the DEA’s decision is subject to further review and public comments before taking effect. Armentano suggested that Congress may need to create new regulatory pathways for cannabis products in the future. This marks the fifth time a cannabis rescheduling petition has been considered by the DEA.
https://norml.org/blog/2024/04/30/dea-accepts-health-agencys-recommendation-to-reclassify-cannabis/